DVT Prevention: What Is Happening in the "Real World"?

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue SUPPL. 1, 2003, Pages 23-31

  Goldhaber, Samuel Z ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Deep venous thrombosis; Prophylaxis; Risk; Venous thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; DESOGESTREL; ESTROGEN; FONDAPARINUX; GESTAGEN; GESTODENE; HEPARIN DERIVATIVE; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; WARFARIN;

ACUTE HEART INFARCTION; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; EPIDEMIOLOGICAL DATA; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HIGH RISK PATIENT; HOSPITAL; HUMAN; LUNG EMBOLISM; MEDICAL SPECIALIST; NURSE; PRIORITY JOURNAL;

EID: 0348047548     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-45414     Document Type: Conference Paper

References (42)

1. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353: 1386-1389
2. McHugh KB, Visani L, DeRosa M, Covezzoli A, Rossi E, Goldhaber SZ. Gender comparisons in pulmonary embolism (results from the International Cooperative Pulmonary Embolism Registry [ICOPER]). Am J Cardiol 2002;89:616-619
3. Nakamura M, Fujioka H, Yamada N, et al. Clinical characteristics of acute pulmonary thromboembolism in Japan: results of a multicenter registry in the Japanese Society of Pulmonary Embolism Research. Clin Cardiol 2001;24:132-138
4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 1999;159:445-453
5. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ III. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998;158:585-593
6. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'étude de la Thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-660
7. Oger E, Bressollette L, Nonent M, et al. High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients. Thromb Haemost 2002;88:592-597
8. Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003;89:493-498
9. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-3420
10. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Polak JF, Folsom AR. Cardiovascular risk factors and venous thromboembolism incidence: the Longitudinal Investigation of Thromboembolism Etiology. Arch Intern Med 2002;162:1182-1189
11. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA 1997;277:642-645
12. Joffe HV, Goldhaber SZ. Upper-extremity deep vein thrombosis. Circulation 2002;106:1874-1880
13. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003;348:1123-1133
14. Chasan-Taber L, Stampfer MJ. Epidemiology of oral contraceptives and cardiovascular disease. Ann Intern Med 1998;128:467-477
15. Jick H, Kaye JA, Vasilakis-Scaramozza C, Jick SS. Risk of venous thromboembolism among users of third-generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis. BMJ 2000;321:1190-1195
16. Greer IA. Thrombosis in pregnancy: maternal and fetal issues. Lancet 1999;353:1258-1265
17. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002;288:872-881
18. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:58-66
19. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
20. Joffe HV, Goldhaber SZ. Laboratory thrombophilias and venous thromboembolism. Vasc Med 2002;7:93-102
21. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779-783
22. National Experts' Consensus Panels for Clinical Excellence in Thrombosis Management. Prophylaxis of venous thromboembolism (VTE) in the hospitalized medical patient. Hospital Medicine Consensus Reports. May 1, 2003:1-18
23. Comerota AJ, Chouhan V, Harada RN, et al. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg 1997;226:306-313
24. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800
25. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ, for the PREVENT Medical Thromboprophylaxis Study Group. A randomized placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ISTH Abstract OC396. Presented on July 18, 2003 in Birmingham, England
26. Gallus AS, Coghlan DW. Heparin pentasaccharide. Curr Opin Hematol 2002;9:422-429
27. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. Lancet 2002;359:1710-1711
28. Bergqvist D, Agnelli G, Cohen AT, et al. Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer. N Engl J Med 2002;346:975-980
29. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001;358:9-15
30. Mismetti P, Laporte-Simitsidis S,Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular- weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19
31. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-1665
32. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ III. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med 2000;160:761-768
33. Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434
34. Kakkar W, Corrigan TP, Fossard DP, et al. Prevention of fatal postoperative pulmonary embolism by low doses of heparin: an International Multicentre Trial. Lancet 1975;2:45-51
35. Collins R, Scrimgeour A, Yusuf S, et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988;318:1162-1173
36. Keane MG, Ingenito EP, Goldhaber SZ. Utilization of venous thromboembolism prophylaxis in the medical intensive care unit. Chest 1994;106:13-14
37. Hirsch DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995;274:335-337
38. Goldhaber SZ. Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. Chest 1998;113:5-7
39. Goldhaber SZ, Dunn K, MacDougall RC. New onset of venous thromboembolism among hospitalized patients at Brigham and Women's Hospital is caused more often by prophylaxis failure than by withholding treatment. Chest 2000;118:1680-1684
40. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(1 suppl):132S-175S
41. Grasso-Correnti N, Goldszer RC, Goldhaber SZ. The critical pathways of an anticoagulation service. Critical Pathways in Cardiology 2003;2:41-45
42. Durieux P, Nizard R, Ravaud P, Mounier N, Lepage E. A clinical decision support system for prevention of venous thromboembolism: effect on physician behavior. JAMA 2000;283:2816-2821